Safety Profile of Paxlovid in the Treatment of COVID-19.
Bing LvXin GaoGuoqiang ZengHui GuoFaping LiPublished in: Current pharmaceutical design (2024)
This study indicates that the most common AEs reported with Paxlovid in post-marketing experience are consistent with the safety assessment of antiviral drugs. Even without emerging apparent safety concerns, the incidence of serious outcomes was unexpectedly high, and a few cases of potential new AEs occurred.